CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q1 2021$1,912,000
+5.3%
93,700
-8.3%
0.00%0.0%
Q4 2020$1,816,000
+17.8%
102,209
-1.9%
0.00%0.0%
Q3 2020$1,541,000
-28.8%
104,209
+1.1%
0.00%
-50.0%
Q2 2020$2,163,000
-7.9%
103,063
+1.4%
0.00%
-33.3%
Q1 2020$2,348,000
-9.9%
101,609
+1.0%
0.00%
+50.0%
Q4 2019$2,605,000
+63.1%
100,622
+22.8%
0.00%0.0%
Q3 2019$1,597,000
+56.0%
81,966
+30.7%
0.00%
+100.0%
Q2 2019$1,024,000
-18.1%
62,715
+13.6%
0.00%
-50.0%
Q1 2019$1,251,000
-13.8%
55,200
-2.6%
0.00%0.0%
Q4 2018$1,451,000
-28.6%
56,700
-8.8%
0.00%
-33.3%
Q3 2018$2,032,000
+33.2%
62,200
-7.6%
0.00%
+50.0%
Q2 2018$1,526,000
-14.3%
67,300
-8.3%
0.00%
-33.3%
Q1 2018$1,780,000
-17.1%
73,400
-4.7%
0.00%0.0%
Q4 2017$2,148,000
-16.6%
77,000
+2.4%
0.00%
-25.0%
Q3 2017$2,575,000
-24.5%
75,200
-12.1%
0.00%
-20.0%
Q2 2017$3,410,000
+11.3%
85,600
+2.9%
0.01%0.0%
Q1 2017$3,063,000
+9.4%
83,200
-5.2%
0.01%0.0%
Q4 2016$2,799,000
-17.6%
87,800
-6.3%
0.01%
-16.7%
Q3 2016$3,396,000
+76.3%
93,700
+10.4%
0.01%
+100.0%
Q2 2016$1,926,000
+16.9%
84,900
-3.1%
0.00%0.0%
Q1 2016$1,647,000
+8.1%
87,600
-5.7%
0.00%
+50.0%
Q4 2015$1,523,000
+49.2%
92,9000.0%0.00%0.0%
Q3 2015$1,021,000
-18.4%
92,900
-3.3%
0.00%0.0%
Q2 2015$1,251,000
-27.5%
96,0690.0%0.00%0.0%
Q1 2015$1,726,0000.0%96,0690.0%0.00%0.0%
Q4 2014$1,726,000
+114.1%
96,069
+174.7%
0.00%
+100.0%
Q3 2014$806,000
-27.7%
34,969
-0.0%
0.00%
-50.0%
Q2 2014$1,115,00034,9710.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders